The Titration Ladder, Plate by Plate

The FDA-labelled titration ladder for tirzepatide begins at 2.5 milligrams once weekly and increases by 2.5 milligrams every four weeks to maintenance doses of five, 7.5, ten, 12.5, or fifteen milligrams once weekly^[1][3]. The starting dose of 2.5 milligrams is explicitly described as a dose-initiation step, not a therapeutic dose for chronic management. Maintenance doses in the type-2-diabetes programme were five, ten, and fifteen milligrams^[1][2], and the obesity programme used the same three maintenance tiers across SURMOUNT-1^[3] and SURMOUNT-5^[9]; intermediate maintenance doses of 7.5 and 12.5 milligrams were introduced to permit clinical titration short of the highest tier.

The four-week interval between dose steps is the protocol-mandated minimum. Gastrointestinal tolerability is the dose-limiting factor during titration; gastrointestinal-related discontinuations have been the leading source of trial attrition^[17]. In SURPASS-1, the three maintenance doses produced HbA1c reductions of 1.87 to 2.07 percent and body-weight reductions of seven to 9.5 kilograms at forty weeks^[1]. In SURMOUNT-1, the same three maintenance doses produced weight reductions of sixteen to 22.5 percent at seventy-two weeks^[3].

Tirzepatide has a mean elimination half-life of approximately five days (roughly one hundred and twenty hours) in humans following subcutaneous administration. Absolute subcutaneous bioavailability is approximately eighty percent and albumin binding is approximately ninety-nine percent. Steady-state is reached at approximately four weeks of once-weekly dosing, with a 1.6-fold accumulation factor; time-to-maximum-concentration after a single subcutaneous dose ranges from eight to seventy-two hours^[5].

The pharmacokinetic profile is the load-bearing reason the titration cadence works the way it does. Each four-week dose-titration interval permits approximately five half-lives of equilibration at the prior dose before the next step — a margin that limits the magnitude of any transient peak concentrations during titration and underwrites the trial protocols' tolerability claims.

The molecular features that produce these pharmacokinetics are themselves worth recording. The C20 fatty diacid conjugated at lysine twenty drives the ninety-nine-percent albumin binding that is the primary determinant of half-life. The α-aminoisobutyric acid substitutions at positions two and thirteen resist DPP-4 and other proteolytic cleavage. These two structural choices together convert what would otherwise be a short-acting peptide into a once-weekly therapy.

Half-life · ~5 days SC bioavailability · ~80% Albumin binding · ~99% Steady-state · ~4 weeks Tmax · 8–72 h

Tirzepatide is administered subcutaneously, in the abdomen, thigh, or upper arm; bioavailability is approximately eighty percent and is site-independent across the studied injection regions^[5]. Population pharmacokinetic analyses observed no clinically meaningful differences across body weights or demographic subgroups within the studied range. Preclinical work in rodents has also used intraperitoneal and, less commonly, intravenous routes for mechanistic and pharmacokinetic single-dose studies^[16].

The label-recommended administration cadence is once weekly on the same day each week, with timing flexibility within the same day. If a dose is missed and the next scheduled dose is at least seventy-two hours away, the missed dose can be administered; otherwise the missed dose is skipped and the next dose is administered on schedule. Storage is refrigerated under standard conditions per the FDA label.

Preclinical rodent studies generally use doses in the range of one to thirty nanomoles per kilogram, administered subcutaneously or intraperitoneally, once daily or every other day. The Parkinson's-model paper, for example, used ten nanomoles per kilogram intraperitoneal^[16]. These figures are useful for orienting in the preclinical literature; they are not converted, dose-extrapolated, or otherwise translated to human equivalents here. Allometric conversion of preclinical incretin doses to human-equivalent doses is not a straightforward exercise and is properly handled in the pharmacokinetic and pharmacodynamic modelling literature, not in editorial commentary.